We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lower Respiratory Tract Pathogens Analyzed by Breath Test

By LabMedica International staff writers
Posted on 14 Jul 2015
Healthcare associated infections, including ventilator associated pneumonia, are difficult to diagnose and treat, and are associated with significant morbidity, mortality and cost.

Chemically analyzing breath volatile profiles that were associated with the presence of clinically relevant pathogens in the lower respiratory tract from patients in intensive care can reveal bacterial infection in ventilated patients at risk of developing pneumonia.

Scientists at the University of Manchester (UK) and their colleagues recruited patients undergoing invasive mechanical ventilation in an intensive care unit. More...
Clinical details related to the patient diagnoses and investigations were recorded, including data related to physiology, radiology, microbiology as well as blood biochemistry and hematology. In addition serum was analyzed for the inflammatory cytokines interleukin (IL)-6, IL-10 and procalcitonin. Samples were collected from 54 patients and assent obtained for 46 consultees between January and July 2010.

A novel sampling apparatus was developed for the specific purpose of capturing volatiles from the distal intratracheal air of mechanically ventilated patients. Analysis of breath samples was performed by thermal desorption/gas chromatography/time-of-flight mass spectrometry (TD/GC-MS, Markes International; Llantrisant, UK), and the GCT Premier mass spectrometer, (Waters Corp; Manchester, UK). Samples were also cultured for pathogens.

The dominant factors affecting breath sample analysis were the individual breath profile and duration of intubation. When these were taken into account, clear separation was seen between breath profiles at each time point by the presence/absence of pathogens. The most commonly isolated pathogens were Haemophilus influenzae found in 12 samples from 10 patients and Staphylococcus aureus found in 18 samples from 10 patients. Thirty-one (67%) patients had negative respiratory and blood culture samples at baseline, and 20 (43%) remained culture-negative for the duration of the study, although only two of these were sampled on more than two occasions.

Compounds found to be lower in concentration in the breath of infected versus non-infected patients included ethanol, 2-methyl cyclopentanone, heptane, and N-cyclohexyl-N′(2-hydroxyethyl)thiourea, while those found in higher concentration included 3-carene, n-butyric acid 2-ethylhexyl ester , nonanal and 2,6,11,15-tetramethyl-hexadecane. Multivariate analysis showed none of the blood inflammatory biomarkers measured, procalcitonin, IL10, IL6, IL10/6 ratio, total white cell count, predicted the presence of lower respiratory tract pathogens.

The authors concluded that volatile metabolites in the breath of ventilated patients at high risk of developing ventilator associated pneumonia (VAP) show distinct patterns that enable the differentiation of patients with and without pathogens in the airway. The study was published in the April 2015 issue of the journal Thorax.

Related Links:

University of Manchester 
Markes International
Waters Corp. 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.